UROMITEXAN INJ
Brand:
UROMITEXAN INJ
Manufacturer:
ZYDUS
Manufacturer Details
ZYDUS
Compositions:
Mesna(sod 2-mercaptoethane sulphonate) 200mg/2ml inj,
|
Strength
|
Rate
|
Packing Style
|
|
200mg/ 2 ml
|
103.89
|
2mlx3 injection
|
List of Related Indications:
- Tox to urin pass du cyclophosm
- Tox to urin pass du ifosfamide
List Of Drugs:
- Mesna(sod 2-mercaptoethane sulphonate)- @ - Cytoprotect Agent
Indication Type Description:
Pharmacology/ Pharmacokinetics
Drug Interaction:
None reported.
Indication:
Prophylactic to reduce incidence of ifofamide-induced haemorrhage.
Adverse Reaction:
G.I.effect, headache, malaise, skin rash. False positive results in diagnostic tests for urine ketones. I.V.administration: Tachycardia and transient hypertension. Oral: Unpleasant taste,yellowing of teeth on prolonged use. Inhalation: Cough,bronchospasm and retrosternal burning.
Contra-Indications:
Pregnancy. Special precautions: False results of tests for ketone bodies in urine, lactation.
Dosages/ Overdosage Etc:
Indications:
Prophylactic to reduce incidence of ifofamide-induced haemorrhage.
Dosage:
Given as IV bolus in a dosage equal to 20% of ifosfamide .dosage(w/w) at the time of ifosfamide administration and 4 and 8 hours after each dose of ifosfamide. Total daily dose of mesna is 60% of the ifosfamide dose.
Patient Information:
Ref - USP PDI Vol II 17th Edition (1997)
1.Allergies-
Tell your doctor if you have ever had any unusual or allergic reaction to
mesna.
2.Pregnancy-
Mesna has not shown to cause birth defects or other problems in humans.
3. Breast-feeding-
It is known whether mesna passes into breast milk. However, this medicine
has not been reported to cause problems in nursing babies.
4.Children-
Although there is no specific information comparing use of mercaptopurine
in children with use in other age groups, this medicine is not expected to
cause different side effects or problems than it does in adults.
5.Older adults-
There is no specific information comparing use of mesna in the elderly with use
in other age groups
Pharmacology/ Pharmacokinetics:
Pharmacology:
Mesna injection is a detoxifying agent to inhibit the haemorrhagic cystitis induced by ifosfamide . In the kidney, the mesna is reduced to the free thiol compound, mesna, which reacts chemically with the urotoxic ifosfamide metabolite.
Pharmacokinetics:
At doses of 2 to 4g its terminal elimination half-life is about 7 hours
Interaction with Food:
Not applicable
Pregnancy and lactation:
Pregnancy:
Mesna should be given to pregnant women only if the potential benefits outweighs the potential risks.
Lactation:
Not known whether mesna is excreted into the breast milk. Because of potential risks, decide whether to discontinue nursing or to discontinue the drug, depending on the importance of the drug to the mother.
